US-led coalition delivers air strike on civilian procession in Iraq — Defense ministryWorld October 22, 18:45
Gazprom supplies to Europe reach record-breaking 590 mln cubic meters on FridayBusiness & Economy October 22, 18:24
Minsk protests against Ukraine's forced return to Kiev of Belavia planeWorld October 22, 14:05
Russian Foreign Ministry: Militants in Aleppo fail assistance delivery, civilians outflowsRussian Politics & Diplomacy October 22, 14:03
Kremlin: Syria’s breakup may become catastrophe for the regionRussian Politics & Diplomacy October 22, 14:00
Kremlin: Common language at Normandy Four talks is not oftenRussian Politics & Diplomacy October 22, 13:56
Kremlin: Extending humanitarian pause in Aleppo is Putin’s independent decisionRussian Politics & Diplomacy October 22, 13:50
Putin offered condolences to families of victims in Mi-8 crash in YamalSociety & Culture October 22, 11:20
Production of Russian flu vaccines in Nicaragua may start on October 22Society & Culture October 22, 7:44
SCOTTSDALE, Arizona, March 20, 2014 /PRNewswire/ -- Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the multimedia assets associated with this release, please visit www.multivu.com
While several leading cancer centers have only begun introducing immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.
In 1951, Dr. Josef M. Issels, MD founded the world's first hospital specializing in integrative oncology based on integrative immunotherapy. He achieved documented complete long-term remissions of standard therapy-resistant cancers. In view of his expertise, Dr. Issels was invited to serve as an expert member of the German Federal Government Commission in the Fight against Cancer from 1981 until his retirement in 1987.
Issels Integrative Immunotherapy distinguishes itself decisively from mere vaccine administration by integrating specific autologous cancer vaccines, such as Dendritic Cell Vaccine, as well as autologous Lymphokine-Activated Killer (LAK) Cells and activated autologous Natural Killer (NK) Cells, which work on the cellular level of the immune system, into a comprehensive immunobiologic core treatment addressing the tumor microenvironment. The Issels strategy enhances the body's complex defense mechanisms, potentiating the efficacy of vaccine and cell therapies, as seen in the case of Jim Gibson.
In March 2003, Jim Gibson commenced the non-toxic Issels Integrative Immunotherapy including dendritic cell vaccine for his recurring small cell lung cancer, which is the most lethal kind of all lung cancers. After 4 weeks of exclusive Issels Immunotherapy he achieved complete tumor remission and is still cancer free and very active 10 years later without any standard therapy.
Nicole Tupper describes her experience with solely using Issels immunobiologic core treatment for her metastatic adenocarcinoma of the appendix: "I found Issels as a last resort. When I came here, I was a mess...and all of a sudden I started making leaps and bounds. In my last ultrasound my 12-centimeter tumor completely disappeared and all my other abdominal tumors reduced to less than half."
Nicole underwent the Issels immunobiologic core treatment at the Issels U.S. out-patient facility, where patients can also receive advanced genetically targeted cancer therapies.
The Issels medical team brings decades of expertise in providing highly personalized comprehensive immunotherapy programs. Vaccine and cell therapies are administered at the most modern facility of the largest private hospital network of 22 hospitals in Mexico, which meets the highest U.S. and international standards. It is the only full-service hospital in Mexico offering integrative medicine.
Visit the Issels website www.issels.com to learn more about the Issels treatment programs and facilities, or watch more videos of patient testimonials.
Ilse Marie Issels, President, Issels Foundation, Inc.